161 related articles for article (PubMed ID: 38355839)
1. Stratifying ICIs-responsive tumor microenvironment in HCC: from parsing out immune-hypoxic crosstalk to clinically applicable MRI-radiomics models.
Song LN; Wang B; Cai JL; Zhang PL; Chen SP; Zhou ZJ; Dai Z
Br J Cancer; 2024 May; 130(8):1356-1364. PubMed ID: 38355839
[TBL] [Abstract][Full Text] [Related]
2. Identification of Novel Tumor Microenvironment-Related Long Noncoding RNAs to Determine the Prognosis and Response to Immunotherapy of Hepatocellular Carcinoma Patients.
Huang S; Zhang J; Lai X; Zhuang L; Wu J
Front Mol Biosci; 2021; 8():781307. PubMed ID: 35004851
[No Abstract] [Full Text] [Related]
3. Prognostic clinical phenotypes associated with tumor stemness in the immune microenvironment of T-cell exhaustion for hepatocellular carcinoma.
Zhang G
Discov Oncol; 2023 Nov; 14(1):203. PubMed ID: 37957420
[TBL] [Abstract][Full Text] [Related]
4. Development of a machine learning-based radiomics signature for estimating breast cancer TME phenotypes and predicting anti-PD-1/PD-L1 immunotherapy response.
Han X; Guo Y; Ye H; Chen Z; Hu Q; Wei X; Liu Z; Liang C
Breast Cancer Res; 2024 Jan; 26(1):18. PubMed ID: 38287356
[TBL] [Abstract][Full Text] [Related]
5. A novel stemness-hypoxia-related signature for prognostic stratification and immunotherapy response in hepatocellular carcinoma.
Zhang G; Zhang K; Zhao Y; Yang Q; Lv X
BMC Cancer; 2022 Oct; 22(1):1103. PubMed ID: 36307751
[TBL] [Abstract][Full Text] [Related]
6. TIGIT/CD155 axis mediates resistance to immunotherapy in patients with melanoma with the inflamed tumor microenvironment.
Kawashima S; Inozume T; Kawazu M; Ueno T; Nagasaki J; Tanji E; Honobe A; Ohnuma T; Kawamura T; Umeda Y; Nakamura Y; Kawasaki T; Kiniwa Y; Yamasaki O; Fukushima S; Ikehara Y; Mano H; Suzuki Y; Nishikawa H; Matsue H; Togashi Y
J Immunother Cancer; 2021 Nov; 9(11):. PubMed ID: 34795004
[TBL] [Abstract][Full Text] [Related]
7. Immune checkpoint inhibitor resistance in hepatocellular carcinoma.
Wang Z; Wang Y; Gao P; Ding J
Cancer Lett; 2023 Feb; 555():216038. PubMed ID: 36529238
[TBL] [Abstract][Full Text] [Related]
8. Development of a novel tumor microenvironment-related radiogenomics model for prognosis prediction in hepatocellular carcinoma.
Wang Y; Gao B; Xia C; Peng X; Liu H; Wu S
Quant Imaging Med Surg; 2023 Sep; 13(9):5803-5814. PubMed ID: 37711809
[TBL] [Abstract][Full Text] [Related]
9. Identification and Validation of a Novel Tumor Microenvironment-Related Prognostic Signature of Patients With Hepatocellular Carcinoma.
Li R; Zhao W; Liang R; Jin C; Xiong H
Front Mol Biosci; 2022; 9():917839. PubMed ID: 35847972
[No Abstract] [Full Text] [Related]
10. Establishment of immune suppression by cancer cells in the tumor microenvironment.
Nishikawa H
Proc Jpn Acad Ser B Phys Biol Sci; 2024; 100(2):114-122. PubMed ID: 38346752
[TBL] [Abstract][Full Text] [Related]
11. Radiomic and clinical data integration using machine learning predict the efficacy of anti-PD-1 antibodies-based combinational treatment in advanced breast cancer: a multicentered study.
Zhao J; Sun Z; Yu Y; Yuan Z; Lin Y; Tan Y; Duan X; Yao H; Wang Y; Liu J
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37217246
[TBL] [Abstract][Full Text] [Related]
12. Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.
Liu Y; Xun Z; Ma K; Liang S; Li X; Zhou S; Sun L; Liu Y; Du Y; Guo X; Cui T; Zhou H; Wang J; Yin D; Song R; Zhang S; Cai W; Meng F; Guo H; Zhang B; Yang D; Bao R; Hu Q; Wang J; Ye Y; Liu L
J Hepatol; 2023 Apr; 78(4):770-782. PubMed ID: 36708811
[TBL] [Abstract][Full Text] [Related]
13. Distinguishing immune checkpoint inhibitor-related pneumonitis from radiation pneumonitis by CT radiomics features in non-small cell lung cancer.
Peiliang Wang MD; Yikun Li MM; Mengyu Zhao MM; Jinming Yu MD; Feifei Teng MD
Int Immunopharmacol; 2024 Feb; 128():111489. PubMed ID: 38266450
[TBL] [Abstract][Full Text] [Related]
14. DNA Damage Repair Status Predicts Opposite Clinical Prognosis Immunotherapy and Non-Immunotherapy in Hepatocellular Carcinoma.
Chen Y; Wang X; Deng X; Zhang Y; Liao R; Li Y; Yang H; Chen K
Front Immunol; 2021; 12():676922. PubMed ID: 34335575
[TBL] [Abstract][Full Text] [Related]
15. Analysis of m6A-Related lncRNAs for Prognosis Value and Response to Immune Checkpoint Inhibitors Therapy in Hepatocellular Carcinoma.
Wang Y; Li N; Tian D; Zhou CW; Wang YH; Yang C; Zeng MS
Cancer Manag Res; 2021; 13():6451-6471. PubMed ID: 34429653
[TBL] [Abstract][Full Text] [Related]
16. Combinatorial targeting of immune checkpoints and epigenetic regulators for hepatocellular carcinoma therapy.
Akce M; El-Rayes BF; Wajapeyee N
Oncogene; 2023 Mar; 42(14):1051-1057. PubMed ID: 36854723
[TBL] [Abstract][Full Text] [Related]
17. Complement and coagulation cascades pathway-related signature as a predictor of immunotherapy in metastatic urothelial cancer.
Gong Z; He Y; Mi X; Li C; Sun X; Wang G; Li L; Han Y; Xu C; Wang W; Cai S; Wang L; Liu Z
Aging (Albany NY); 2023 Sep; 15(18):9479-9498. PubMed ID: 37747262
[TBL] [Abstract][Full Text] [Related]
18. Crosstalk Between the Tumor Microenvironment and Cancer Cells: A Promising Predictive Biomarker for Immune Checkpoint Inhibitors.
Li X; Yang Y; Huang Q; Deng Y; Guo F; Wang G; Liu M
Front Cell Dev Biol; 2021; 9():738373. PubMed ID: 34692696
[TBL] [Abstract][Full Text] [Related]
19. Development of a TMErisk model based on immune infiltration in tumour microenvironment to predict prognosis of immune checkpoint inhibitor treatment in hepatocellular carcinoma.
Yan ZJ; Yu CT; Chen L; Wang HY
Brief Bioinform; 2023 Mar; 24(2):. PubMed ID: 36882021
[TBL] [Abstract][Full Text] [Related]
20. TNFR2 expression predicts the responses to immune checkpoint inhibitor treatments.
Liao P; Jiang M; Islam MS; Wang Y; Chen X
Front Immunol; 2023; 14():1097090. PubMed ID: 36865537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
